Scholarlink

Introduction <p>People with multiple sclerosis (pwMS) have an increased risk of infections. There are limited data characterizing who initially diagnoses infections in pwMS and how these are communicated among healthcare providers.</p> Methods <p>Retrospective US claims data from January 1, 2017 to August 31, 2024 were used to identify newly diagnosed pwMS aged 18–64&#xa0;years who were taking any disease-modifying therapy (DMT) for ≥ 90&#xa0;days. Index date was the earliest date of the first DMT claim. Infections were based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Severe infections included events requiring hospitalization and/or intravenous antibiotics.</p> Results <p>Overall, 69,148 pwMS who were treatment-naïve met eligibility criteria. Mean age was 44.1&#xa0;years; 72% were female; and 81% were &lt; 1&#xa0;year from initial MS diagnosis to DMT initiation. A total of 316,497 infection events were reported over the study period, with 98% first reported by non-neurology providers. There were 21,416 severe infection events reported, of which &gt; 98% were first reported by non-neurologists. In pwMS with infection events first reported by non-neurologists, 6% had a neurology visit ≤ 7&#xa0;days after initial infection; of those, 8% had any infection ICD-10-CM code recorded at that visit (increased to 19% for serious infections). In the 16% of pwMS with a neurology visit ≤ 30&#xa0;days post initial infection reported by a non-neurologist, 6% had any infection ICD-10-CM code recorded at that neurology visit (increased to 14% for severe infections).</p> Conclusion <p>Most infections in pwMS are first reported by non-neurology providers, as most pwMS did not interact with their MS clinician in the first few months after infection, even if that infection was severe. These data highlight the importance of communication between different providers and patients to accurately assess patient status and DMT safety, leading to improved patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Peiqing Qian,
  • Jenna Brunn,
  • Wennifer Giglio,
  • Kelly Holmes,
  • Elijah Lackey,
  • Jong-Mi Lee,
  • Gabriel Pardo,
  • James B. Lewin,
  • Danette Rutledge,
  • Nicholas Belviso,
  • Babak Amerian-Williams

摘要

Introduction

People with multiple sclerosis (pwMS) have an increased risk of infections. There are limited data characterizing who initially diagnoses infections in pwMS and how these are communicated among healthcare providers.

Methods

Retrospective US claims data from January 1, 2017 to August 31, 2024 were used to identify newly diagnosed pwMS aged 18–64 years who were taking any disease-modifying therapy (DMT) for ≥ 90 days. Index date was the earliest date of the first DMT claim. Infections were based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Severe infections included events requiring hospitalization and/or intravenous antibiotics.

Results

Overall, 69,148 pwMS who were treatment-naïve met eligibility criteria. Mean age was 44.1 years; 72% were female; and 81% were < 1 year from initial MS diagnosis to DMT initiation. A total of 316,497 infection events were reported over the study period, with 98% first reported by non-neurology providers. There were 21,416 severe infection events reported, of which > 98% were first reported by non-neurologists. In pwMS with infection events first reported by non-neurologists, 6% had a neurology visit ≤ 7 days after initial infection; of those, 8% had any infection ICD-10-CM code recorded at that visit (increased to 19% for serious infections). In the 16% of pwMS with a neurology visit ≤ 30 days post initial infection reported by a non-neurologist, 6% had any infection ICD-10-CM code recorded at that neurology visit (increased to 14% for severe infections).

Conclusion

Most infections in pwMS are first reported by non-neurology providers, as most pwMS did not interact with their MS clinician in the first few months after infection, even if that infection was severe. These data highlight the importance of communication between different providers and patients to accurately assess patient status and DMT safety, leading to improved patient outcomes.